Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort

Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort

ObjectiveTo compare the real-world clinical efficacy and safety of interleukin (IL)-17A inhibitors (secukinumab [SEC] and ixekizumab [IXE]) versus the IL-23 inhibitor guselkumab (GUS) in patients with nail psoriasis, with a focus on site-specific biologic therapeutic responses (nail matrix vs. nail...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiamei Yan, Minglan Shi, Bin Wang, Lihua Zeng, Huiwei Wang, Jialiang Shi, Yaqian Cui, Suchun Hou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
nail psoriasis
dermoscopy
IL-17A inhibitors
IL-23 inhibitor
real-world cohort
NAPSI
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573715/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573715/full

Similar Items